RxDoctor Payments DataLook up a doctor →

Shannon Ghizzoni, PA

Medical · Columbus, OHNPI 1205998432

Payments from drug & device makers

$116,475in general payments, 2019–2025

Across 1,005 payments — averaging $115.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$70K
  • UCB, Inc.$15K
  • Johnson & Johnson$13K
  • Amgen$7K
  • Novartis$6K
  • Sobi, Inc$2K
  • plus $4K from 21 others

What the payments were for

  • Consulting fees$19,22517%
  • Speaking & faculty fees$68,38359%
  • Travel & lodging$12,39111%
  • Food & beverage$16,40714%
  • Education$690%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$116,475 in reported general payments places this provider in the 95th percentile of 547 medical providers in Ohio.

See all medical providers in Ohio

Medicare billing

Part B allowed, 2024
$224,074
Medicare patients
308
Services billed
21,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab35$321,227
Enbrel MiniEtanercept18$142,223
RinvoqUpadacitinib17$116,081
HumiraAdalimumab14$99,343
Xeljanz XrTofacitinib Citrate13$75,082
ActemraTocilizumab11$52,722
Hydroxychloroquine Sulfate309$14,301
Celecoxib129$9,348
MethotrexateMethotrexate Sodium402$9,188
Leflunomide184$8,469
Cevimeline Hcl36$5,834
Gabapentin309$5,055
Pregabalin113$4,083
Tramadol Hcl223$2,573
Azathioprine63$2,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira$70,305$215,42531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 547 medical providers in Ohio.

Other medical in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →